Anthracycline-Antibody Conjugates for Cancer Therapy
AssigneeImmunomedics, Inc.
InventorsGary L. Griffiths, Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.
Claims13
A method of treating a CD74-expressing cancer, comprising administering to a human subject with a CD74-expressing cancer a conjugate of an anthracycline drug and a humanized anti-CD74 antibody or antigen-binding fragment thereof, wherein the antibody or fragment thereof comprises human antibody framework (FR) and constant region sequences, wherein the humanized anti-CD74 antibody competes for binding to CD74 with an LL1 antibody comprising the light chain complementarity determining region (CDR) sequences CDR1 (RSSQSLVHRNGNTYLH, SEQ ID NO:1), CDR2 (TVSNRFS, SEQ ID NO:2) and CDR3 (SQSSHVPPT, SEQ ID NO:3) and heavy chain CDR1 (NYGVN, SEQ ID NO:4), CDR2 (WINPNTGEPTFDDDFKG, SEQ ID NO:5), and CDR3 (SRGKNEAWFAY, SEQ ID NO:6).
Dependencies are inferred from the claim text.